Chul Hyoung Lyoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chul Hyoung Lyoo has a total of 471 co-authors. Here are the top co-authors by number of shared publications:
- Myung Sik Lee
Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea
62 shared publications - Young Hoon Ryu
Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University, College of Medicine, Seoul, South Korea
51 shared publications - Hanna Cho
Department of Neurology Gangnam Severance Hospital Yonsei University College of Medicine Seoul South Korea
34 shared publications Jae Yong Choi
Yonsei University College of Medicine
25 shared publications- Joong-Seok Kim
Department of Neurology, Yonsei University College of Medicine, Seoul, Korea
19 shared publications Jae Hoon Lee
Department of Nuclear Medicine Gangnam Severance Hospital Yonsei University College of Medicine Seoul South Korea
17 shared publications
Latest Publications
- 3 September 2026
- Published by Wiley in Movement Disorders
Distinct Spatiotemporal Patterns of Dopaminergic and Metabolic Imaging in De Novo Parkinson's Disease
Background: Understanding the heterogeneity of Parkinson's disease (PD) is essential to guide patient care, prognosis, and treatment. Objective: We used 18 F‐fluorodeoxyglucose ( 18 F‐FDG) positron emission tomography (PET), 18 F‐ N ‐(3‐fluoropropyl)‐2β‐carbomethoxy‐3β‐(4‐iodophenyl) nortropane ( 18 F‐FP‐CIT) PET, and Subtype and Stage Inference (SuStaIn) algorithm to define subtypes in drug‐naive patients with PD. Methods: A total of 147 de novo PD patients and 38 healthy individuals who underwent 18 F‐FDG PET, 18 F‐FP‐CIT, and brain magnetic resonance imaging were enrolled. The SuStaIn algorithm was employed to identify FP‐CIT– and FDG‐based subtypes. Motor and nonmotor features were compared between them. Correlations were analyzed to assess the associations between the progression stage and motor or cognitive scores within each subtype. Results: Two distinct subtypes were identified: subtype 1 (fronto‐striatal hypometabolic) and subtype 2 (mixed hypermetabolic – posterior hypometabolic). In subtype 1, striatal dopamine transporter (DAT) loss was accompanied by decreases in frontal and caudate metabolism at earlier stages, whereas hypometabolism in the posterior cortical and limbic regions appeared at later stages. In subtype 2, striatal DAT deficit and hypermetabolism of the putamen, medial temporal, and anterior cingulate cortices and lateral occipital hypometabolism appeared in the early stages. This metabolic reduction subsequently involved parieto‐temporal, frontal, and limbic regions. Motor deficits were comparable between the subtypes. Those with subtype 2 exhibited poorer cognitive and olfactory performance, higher anxiety scores, higher Rapid Eye Movement Behavior Disorder Screening Questionnaire scores, and lower putaminal DAT availability and asymmetry than in subtype 1. The stage correlated with cognitive decline only in subtype 2, with a marginally significant stage‐by‐group interaction. Conclusions: De novo PD can be classified into two distinct metabolic subtypes: fronto‐striatal hypometabolic and mixed hypermetabolic – posterior hypometabolic, with nonmotor manifestations being more severe in the latter. © 2026 International Parkinson and Movement Disorder Society.
- 3 September 2026
- Published by Wiley in Movement Disorders
Distinct Spatiotemporal Patterns of Dopaminergic and Metabolic Imaging in De Novo Parkinson's Disease
Background: Understanding the heterogeneity of Parkinson's disease (PD) is essential to guide patient care, prognosis, and treatment. Objective: We used 18 F‐fluorodeoxyglucose ( 18 F‐FDG) positron emission tomography (PET), 18 F‐ N ‐(3‐fluoropropyl)‐2β‐carbomethoxy‐3β‐(4‐iodophenyl) nortropane ( 18 F‐FP‐CIT) PET, and Subtype and Stage Inference (SuStaIn) algorithm to define subtypes in drug‐naive patients with PD. Methods: A total of 147 de novo PD patients and 38 healthy individuals who underwent 18 F‐FDG PET, 18 F‐FP‐CIT, and brain magnetic resonance imaging were enrolled. The SuStaIn algorithm was employed to identify FP‐CIT– and FDG‐based subtypes. Motor and nonmotor features were compared between them. Correlations were analyzed to assess the associations between the progression stage and motor or cognitive scores within each subtype. Results: Two distinct subtypes were identified: subtype 1 (fronto‐striatal hypometabolic) and subtype 2 (mixed hypermetabolic – posterior hypometabolic). In subtype 1, striatal dopamine transporter (DAT) loss was accompanied by decreases in frontal and caudate metabolism at earlier stages, whereas hypometabolism in the posterior cortical and limbic regions appeared at later stages. In subtype 2, striatal DAT deficit and hypermetabolism of the putamen, medial temporal, and anterior cingulate cortices and lateral occipital hypometabolism appeared in the early stages. This metabolic reduction subsequently involved parieto‐temporal, frontal, and limbic regions. Motor deficits were comparable between the subtypes. Those with subtype 2 exhibited poorer cognitive and olfactory performance, higher anxiety scores, higher Rapid Eye Movement Behavior Disorder Screening Questionnaire scores, and lower putaminal DAT availability and asymmetry than in subtype 1. The stage correlated with cognitive decline only in subtype 2, with a marginally significant stage‐by‐group interaction. Conclusions: De novo PD can be classified into two distinct metabolic subtypes: fronto‐striatal hypometabolic and mixed hypermetabolic – posterior hypometabolic, with nonmotor manifestations being more severe in the latter. © 2026 International Parkinson and Movement Disorder Society.
- Open Access
- 28 July 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (9) , 2299-2309
Greater Motor and Nonmotor Burden at Diagnosis Is Associated With Amyloid Copathology in Parkinson's Disease
Background: Concurrent Alzheimer's disease pathology is increasingly recognized as a poor prognostic factor in Parkinson's disease (PD), yet reliable clinical indicators for early identification of AD copathology remain poorly established. Objective: To investigate baseline motor and nonmotor symptom profiles associated with amyloid‐β (Aβ) copathology in newly diagnosed PD. Methods: Among patients with PD who underwent Aβ imaging, we retrospectively identified 152 patients who completed the Cross‐Cultural Smell Identification Test (CC‐SIT), autonomic function tests, neuropsychological assessment, and Neuropsychiatric Inventory Questionnaire (NPI‐Q) at drug‐naive state. Predictors of Aβ positivity were identified using stepwise multivariable logistic regression and validated with Random Forest classifiers employing Boruta feature selection. Results: Compared with Aβ‐negative counterparts (n = 93), Aβ‐positive (Aβ + PD, n = 59) patients demonstrated greater olfactory dysfunction (CC‐SIT, P = 0.002), dysautonomia (Composite Autonomic Severity Scale [CASS], P < 0.001), and mood disturbance (NPI‐Q‐mood, P < 0.001) and higher prevalence of probable rapid eye movement sleep behavior disorder ( P = 0.009) and neurogenic orthostatic hypotension ( P = 0.006). Aβ + PD patients showed greater motor disability (Unified Parkinson's Disease Rating Scale Part III [UPDRS‐III], P < 0.001) despite comparable striatal dopamine transporter uptake. Logistic regression identified lower CC‐SIT scores (odds ratio [OR] = 0.821, 95% confidence interval [CI 95% ]: 0.703–0.959), higher CASS scores (OR = 1.380, CI 95% : 1.144–1.666), higher NPI‐Q‐mood scores (OR = 1.057, CI 95% : 1.005–1.111), higher UPDRS‐III (OR = 1.080, CI 95% : 1.030–1.132), and APOE ε4 carrier status (OR = 3.643, CI 95% : 1.479–8.969) as independent predictors of Aβ positivity, which were also confirmed as important variables by Boruta feature selection. Conclusions: Our findings suggest that greater motor and nonmotor symptom burden at diagnosis, characterized by olfactory/autonomic dysfunction, mood disturbance, and motor deficits disproportionate to dopaminergic denervation, was associated with Aβ positivity in PD. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 28 July 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (9) , 2299-2309
Open AccessGreater Motor and Nonmotor Burden at Diagnosis Is Associated With Amyloid Copathology in Parkinson's Disease
Background: Concurrent Alzheimer's disease pathology is increasingly recognized as a poor prognostic factor in Parkinson's disease (PD), yet reliable clinical indicators for early identification of AD copathology remain poorly established. Objective: To investigate baseline motor and nonmotor symptom profiles associated with amyloid‐β (Aβ) copathology in newly diagnosed PD. Methods: Among patients with PD who underwent Aβ imaging, we retrospectively identified 152 patients who completed the Cross‐Cultural Smell Identification Test (CC‐SIT), autonomic function tests, neuropsychological assessment, and Neuropsychiatric Inventory Questionnaire (NPI‐Q) at drug‐naive state. Predictors of Aβ positivity were identified using stepwise multivariable logistic regression and validated with Random Forest classifiers employing Boruta feature selection. Results: Compared with Aβ‐negative counterparts (n = 93), Aβ‐positive (Aβ + PD, n = 59) patients demonstrated greater olfactory dysfunction (CC‐SIT, P = 0.002), dysautonomia (Composite Autonomic Severity Scale [CASS], P < 0.001), and mood disturbance (NPI‐Q‐mood, P < 0.001) and higher prevalence of probable rapid eye movement sleep behavior disorder ( P = 0.009) and neurogenic orthostatic hypotension ( P = 0.006). Aβ + PD patients showed greater motor disability (Unified Parkinson's Disease Rating Scale Part III [UPDRS‐III], P < 0.001) despite comparable striatal dopamine transporter uptake. Logistic regression identified lower CC‐SIT scores (odds ratio [OR] = 0.821, 95% confidence interval [CI 95% ]: 0.703–0.959), higher CASS scores (OR = 1.380, CI 95% : 1.144–1.666), higher NPI‐Q‐mood scores (OR = 1.057, CI 95% : 1.005–1.111), higher UPDRS‐III (OR = 1.080, CI 95% : 1.030–1.132), and APOE ε4 carrier status (OR = 3.643, CI 95% : 1.479–8.969) as independent predictors of Aβ positivity, which were also confirmed as important variables by Boruta feature selection. Conclusions: Our findings suggest that greater motor and nonmotor symptom burden at diagnosis, characterized by olfactory/autonomic dysfunction, mood disturbance, and motor deficits disproportionate to dopaminergic denervation, was associated with Aβ positivity in PD. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 26 May 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (10) , e214812
Functional Reorganization of Corticostriatal Connectivity Across the Degree of Nigrostriatal Degeneration in Parkinson Disease
Background and ObjectivesIn Parkinson disease (PD), deafferentation of nigral dopaminergic neurons to the striatum leads to striatal dopamine depletion and impaired direct and indirect basal gangli...
- 26 May 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (10) , e214812
Functional Reorganization of Corticostriatal Connectivity Across the Degree of Nigrostriatal Degeneration in Parkinson Disease
Background and ObjectivesIn Parkinson disease (PD), deafferentation of nigral dopaminergic neurons to the striatum leads to striatal dopamine depletion and impaired direct and indirect basal gangli...
- 10 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (3) , e214573
Cerebral Perfusion and Motor Deficits in Drug-Induced Parkinsonism
Drug-induced parkinsonism (DIP) is the second most common cause of parkinsonism after Parkinson disease (PD). It is crucial to diagnose DIP in patients presenting with parkinsonian symptoms because discontinuation of the offending drug can improve parkinsonism. However, the detailed pathophysiology of parkinsonism related to striatal dopamine receptor blockade and disease-specific cerebral changes remains unclear. In this cross-sectional study, we recruited patients with DIP who underwent the Unified Parkinson's Disease Rating Scale (UPDRS) assessment, brain MRI, and dual-phase 18F-FP-CIT PET. The offending drugs were gastrointestinal prokinetics (DIPGI) and antipsychotics (DIPAP). In addition, we enrolled early and drug-naïve patients with PD and healthy controls (HCs). We compared early-phase 18F-FP-CIT uptakes between DIP, PD, and HC groups and investigated its association with the UPDRS part III total score. We calculated the DIP-related perfusion patterns using W-scores, compared their expression among groups, and analyzed their diagnostic performance. Age at PET scan, sex, and vascular risk factors were included as covariates. Compared with patients with PD (n = 160, mean age 68.9 ± 7.9 years; 74 men), the DIP group (n = 72, mean age 67.9 ± 12.9 years; 25 men) exhibited more profound hyperperfusion in the motor-related brain circuit and prominent hypoperfusion in widespread brain regions except for the occipital cortex than HCs (n = 62, mean age 66.9 ± 9.0 years; 25 men). In particular, the DIPGI group (n = 23) showed relative hypoperfusion in the lateral prefrontal, insular, inferior parietal, and cingulate cortices. In the DIP group, UPDRS part III total score was not correlated with striatal dopamine deficits but was associated with the degree of relative perfusion in the prefrontal, insular, and cingulate cortices. By contrast, the UPDRS part III total score in the PD group was not correlated with cerebral perfusion but was associated with striatal dopamine depletion, especially in the posterior putamen. The DIP-related cerebral perfusion pattern effectively discriminated patients with DIP from HCs and patients with PD. Blockage of dopamine receptors by drugs is associated with characteristic cerebral perfusion patterns that are distinct from those in patients with PD and correlate with symptom severity.
- 10 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (3) , e214573
Cerebral Perfusion and Motor Deficits in Drug-Induced Parkinsonism
Drug-induced parkinsonism (DIP) is the second most common cause of parkinsonism after Parkinson disease (PD). It is crucial to diagnose DIP in patients presenting with parkinsonian symptoms because discontinuation of the offending drug can improve parkinsonism. However, the detailed pathophysiology of parkinsonism related to striatal dopamine receptor blockade and disease-specific cerebral changes remains unclear. In this cross-sectional study, we recruited patients with DIP who underwent the Unified Parkinson's Disease Rating Scale (UPDRS) assessment, brain MRI, and dual-phase 18F-FP-CIT PET. The offending drugs were gastrointestinal prokinetics (DIPGI) and antipsychotics (DIPAP). In addition, we enrolled early and drug-naïve patients with PD and healthy controls (HCs). We compared early-phase 18F-FP-CIT uptakes between DIP, PD, and HC groups and investigated its association with the UPDRS part III total score. We calculated the DIP-related perfusion patterns using W-scores, compared their expression among groups, and analyzed their diagnostic performance. Age at PET scan, sex, and vascular risk factors were included as covariates. Compared with patients with PD (n = 160, mean age 68.9 ± 7.9 years; 74 men), the DIP group (n = 72, mean age 67.9 ± 12.9 years; 25 men) exhibited more profound hyperperfusion in the motor-related brain circuit and prominent hypoperfusion in widespread brain regions except for the occipital cortex than HCs (n = 62, mean age 66.9 ± 9.0 years; 25 men). In particular, the DIPGI group (n = 23) showed relative hypoperfusion in the lateral prefrontal, insular, inferior parietal, and cingulate cortices. In the DIP group, UPDRS part III total score was not correlated with striatal dopamine deficits but was associated with the degree of relative perfusion in the prefrontal, insular, and cingulate cortices. By contrast, the UPDRS part III total score in the PD group was not correlated with cerebral perfusion but was associated with striatal dopamine depletion, especially in the posterior putamen. The DIP-related cerebral perfusion pattern effectively discriminated patients with DIP from HCs and patients with PD. Blockage of dopamine receptors by drugs is associated with characteristic cerebral perfusion patterns that are distinct from those in patients with PD and correlate with symptom severity.
- Open Access
- 18 November 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (1) , 87-98
Association of dopamine depletion and cholinergic basal forebrain atrophy with brain metabolism and cognition in Parkinson's disease
Background: Cognitive dysfunction is one of the most debilitating non-motor symptoms of Parkinson's disease (PD). This study aimed to explore the interplay between altered neurotransmitter activities, including dopamine and acetylcholine, and brain metabolism in cognitive decline in PD. Methods: We enrolled 172 PD patients (mean ± SD age 69.8 ± 8.6 years; 93 females) who underwent brain magnetic resonance imaging, N -(3-[ 18 F]fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) nortropane ( 18 F-FP-CIT) positron emission tomography (PET), 18 F-fluorodeoxyglucose (FDG) PET, and neuropsychological testing. General linear models and mediation analyses were used to investigate the association between striatal dopamine transporter (DAT) availability or basal forebrain (BF) volume, brain metabolism, and domain-specific cognitive scores. Results: A significant relationship between caudate dopamine depletion and posterior BF atrophy was found in PD patients. Caudate and putaminal dopamine depletion were associated with altered brain metabolism in regions where PD patients showed decreased metabolism compared with healthy controls, whereas atrophy in the posterior BF was associated with hypometabolism in the lateral prefrontal, orbitofrontal, inferior parietal, and lateral temporal cortices as well as in the precuneus, with a significant interaction between caudate DAT availability and posterior BF volume. Caudate dopamine depletion was associated with visuospatial, memory, and executive dysfunction, whereas posterior BF atrophy was additionally associated with attention. Mediation analyses revealed that visuospatial dysfunction was associated with caudate dopamine depletion or posterior BF atrophy via altered brain metabolism, while executive dysfunction was linked to both directly and through metabolism changes. Conclusions: Caudate dopaminergic and posterior BF cholinergic deficits are interrelated and affect cognition in a domain-specific manner, either directly or through the mediation of altered brain metabolism.
- 18 November 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 16 (1) , 87-98
Open AccessAssociation of dopamine depletion and cholinergic basal forebrain atrophy with brain metabolism and cognition in Parkinson's disease
Background: Cognitive dysfunction is one of the most debilitating non-motor symptoms of Parkinson's disease (PD). This study aimed to explore the interplay between altered neurotransmitter activities, including dopamine and acetylcholine, and brain metabolism in cognitive decline in PD. Methods: We enrolled 172 PD patients (mean ± SD age 69.8 ± 8.6 years; 93 females) who underwent brain magnetic resonance imaging, N -(3-[ 18 F]fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) nortropane ( 18 F-FP-CIT) positron emission tomography (PET), 18 F-fluorodeoxyglucose (FDG) PET, and neuropsychological testing. General linear models and mediation analyses were used to investigate the association between striatal dopamine transporter (DAT) availability or basal forebrain (BF) volume, brain metabolism, and domain-specific cognitive scores. Results: A significant relationship between caudate dopamine depletion and posterior BF atrophy was found in PD patients. Caudate and putaminal dopamine depletion were associated with altered brain metabolism in regions where PD patients showed decreased metabolism compared with healthy controls, whereas atrophy in the posterior BF was associated with hypometabolism in the lateral prefrontal, orbitofrontal, inferior parietal, and lateral temporal cortices as well as in the precuneus, with a significant interaction between caudate DAT availability and posterior BF volume. Caudate dopamine depletion was associated with visuospatial, memory, and executive dysfunction, whereas posterior BF atrophy was additionally associated with attention. Mediation analyses revealed that visuospatial dysfunction was associated with caudate dopamine depletion or posterior BF atrophy via altered brain metabolism, while executive dysfunction was linked to both directly and through metabolism changes. Conclusions: Caudate dopaminergic and posterior BF cholinergic deficits are interrelated and affect cognition in a domain-specific manner, either directly or through the mediation of altered brain metabolism.
- Open Access
- 4 November 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (11) , e70404
Olfactory Dysfunction as a Window Into the Heterogeneity of Parkinson Disease
Background: While olfactory dysfunction is common in Parkinson disease (PD), its neural basis and clinical implications remain to be clarified. We investigated the neural substrates and clinical profiles, particularly non‐motor symptoms (NMSs), associated with olfactory function. Methods: This retrospective study included 259 drug‐naïve patients with PD who underwent the Cross‐Cultural Smell Identification Test (CC‐SIT), comprehensive autonomic function test, neuropsychological assessments, and the Neuropsychiatric Inventory Questionnaire (NPI‐Q) at diagnosis. NMS profiles were compared across olfactory groups defined by CC‐SIT scores (normosmia [ n = 45], hyposmia [ n = 143], anosmia [ n = 74]). Associations between olfaction and clinical/imaging variables were assessed using correlation and path analyses. Cox proportional hazards models were employed to evaluate the risk of developing motor complications or PD dementia according to olfactory status. Results: CC‐SIT scores correlated with Composite Autonomic Severity Scale scores (rho = −0.219, p = 0.001), NPI‐Q scores (rho = −0.269, p < 0.001), and cognitive performance in memory (rho = 0.288, p < 0.001) and frontal/executive domains (rho = 0.205, p = 0.001). Dopaminergic depletion in the caudate nucleus and limbic atrophy emerged as neural substrates underlying olfactory dysfunction, mediating the association between olfaction and cognitive/neuropsychiatric symptoms. Anosmia was associated with increased risk of developing PD dementia compared to normosmia (hazard ratio [HR]: 2.579; 95% confidence intervals [CI]: 1.137–5.851) and hyposmia (HR: 2.783; 95% CI: 1.437–5.390). Anosmia was associated with higher risk of developing freezing of gait (HR: 2.571; 95% CI: 1.077–6.134) compared to normosmia. Conclusions: Olfactory dysfunction serves as a multifaceted clinical marker associated with convergent degeneration of nigrostriatal and limbic pathways, offering insights into PD phenotypic variance and its prognostic implications.
- 4 November 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (11) , e70404
Open AccessOlfactory Dysfunction as a Window Into the Heterogeneity of Parkinson Disease
Background: While olfactory dysfunction is common in Parkinson disease (PD), its neural basis and clinical implications remain to be clarified. We investigated the neural substrates and clinical profiles, particularly non‐motor symptoms (NMSs), associated with olfactory function. Methods: This retrospective study included 259 drug‐naïve patients with PD who underwent the Cross‐Cultural Smell Identification Test (CC‐SIT), comprehensive autonomic function test, neuropsychological assessments, and the Neuropsychiatric Inventory Questionnaire (NPI‐Q) at diagnosis. NMS profiles were compared across olfactory groups defined by CC‐SIT scores (normosmia [ n = 45], hyposmia [ n = 143], anosmia [ n = 74]). Associations between olfaction and clinical/imaging variables were assessed using correlation and path analyses. Cox proportional hazards models were employed to evaluate the risk of developing motor complications or PD dementia according to olfactory status. Results: CC‐SIT scores correlated with Composite Autonomic Severity Scale scores (rho = −0.219, p = 0.001), NPI‐Q scores (rho = −0.269, p < 0.001), and cognitive performance in memory (rho = 0.288, p < 0.001) and frontal/executive domains (rho = 0.205, p = 0.001). Dopaminergic depletion in the caudate nucleus and limbic atrophy emerged as neural substrates underlying olfactory dysfunction, mediating the association between olfaction and cognitive/neuropsychiatric symptoms. Anosmia was associated with increased risk of developing PD dementia compared to normosmia (hazard ratio [HR]: 2.579; 95% confidence intervals [CI]: 1.137–5.851) and hyposmia (HR: 2.783; 95% CI: 1.437–5.390). Anosmia was associated with higher risk of developing freezing of gait (HR: 2.571; 95% CI: 1.077–6.134) compared to normosmia. Conclusions: Olfactory dysfunction serves as a multifaceted clinical marker associated with convergent degeneration of nigrostriatal and limbic pathways, offering insights into PD phenotypic variance and its prognostic implications.
- Open Access
- 14 August 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (8) , e70598
Neural basis of motor symptoms in Alzheimer's disease: role of regional tau burden and cognition
INTRODUCTION: With accumulating evidence that motor manifestations in Alzheimer's disease (AD) may emerge from AD pathology independent of other copathologies, we investigated the neural basis of motor dysfunction under the amyloid/tau/neurodegeneration (ATN) framework.METHODS: This study included 125 patients with AD, excluding individuals with severe leukoaraiosis or comorbid Lewy body features beyond Parkinsonism. Associations of ATN burden with motor dysfunction were tested using multivariate regression models, followed by mediation analyses exploring the cognitive contribution to these associations.RESULTS: Tau burden in the prefrontal, sensorimotor, and parietal regions was associated with motor dysfunction independent of amyloid or neurodegeneration. The effect of parietal tau on motor function was fully mediated by visuospatial dysfunction, whereas prefrontal/sensorimotor tau exerted direct effects without cognitive mediation.DISCUSSION: Increased tau burden in the sensorimotor and frontoparietal association cortices may elicit motor dysfunction in AD through either cognition‐dependent or cognition‐independent mechanisms, with effects depending on the affected regions.Highlights: Tau burden was intimately associated with motor symptoms independent of Aβ or atrophy. Tau in sensorimotor and frontoparietal association cortices may elicit motor symptoms. Prefrontal/sensorimotor tau exerted cognition‐independent effects on motor symptoms. Parietal tau indirectly influenced motor symptoms through visuospatial dysfunction. Parietal tau‐related motor dysfunction may be partly explained by apraxic features.
- 14 August 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (8) , e70598
Open AccessNeural basis of motor symptoms in Alzheimer's disease: role of regional tau burden and cognition
INTRODUCTION: With accumulating evidence that motor manifestations in Alzheimer's disease (AD) may emerge from AD pathology independent of other copathologies, we investigated the neural basis of motor dysfunction under the amyloid/tau/neurodegeneration (ATN) framework.METHODS: This study included 125 patients with AD, excluding individuals with severe leukoaraiosis or comorbid Lewy body features beyond Parkinsonism. Associations of ATN burden with motor dysfunction were tested using multivariate regression models, followed by mediation analyses exploring the cognitive contribution to these associations.RESULTS: Tau burden in the prefrontal, sensorimotor, and parietal regions was associated with motor dysfunction independent of amyloid or neurodegeneration. The effect of parietal tau on motor function was fully mediated by visuospatial dysfunction, whereas prefrontal/sensorimotor tau exerted direct effects without cognitive mediation.DISCUSSION: Increased tau burden in the sensorimotor and frontoparietal association cortices may elicit motor dysfunction in AD through either cognition‐dependent or cognition‐independent mechanisms, with effects depending on the affected regions.Highlights: Tau burden was intimately associated with motor symptoms independent of Aβ or atrophy. Tau in sensorimotor and frontoparietal association cortices may elicit motor symptoms. Prefrontal/sensorimotor tau exerted cognition‐independent effects on motor symptoms. Parietal tau indirectly influenced motor symptoms through visuospatial dysfunction. Parietal tau‐related motor dysfunction may be partly explained by apraxic features.
- Open Access
- 20 February 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 11 (1) , 1-9
Subregion-specific associations of the basal forebrain with sleep and cognition in Parkinson’s disease
To elucidate the role of basal forebrain (BF) in non-motor symptoms of Parkinson’s disease (PD), we investigated the association of sleep quality and cognition with BF volume and functional connectivity. The gray matter volume of the anterior intermediate part (Ch4ai) and the anterior lateral part (Ch4al) of the nucleus basalis Meynert were negatively associated with the PSQI global score. The posterior part of the nucleus basalis Meynert (Ch4p) volume was positively associated with visuospatial, memory, and executive functions. The PSQI global score correlated positively with functional connectivity from the Ch4al to the posterior cingulate, inferior parietal, anterior temporal, and medial prefrontal cortices, which correspond to the default mode network. Our results demonstrated that reduced volume of the anterior portion of the Ch4 and its aberrantly increased functional connectivity with the default mode network were closely related to poor overall sleep quality, while reduced volume of the posterior portion of the Ch4 was associated with decreased cognitive function in PD.
- 20 February 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 11 (1) , 1-9
Open AccessSubregion-specific associations of the basal forebrain with sleep and cognition in Parkinson’s disease
To elucidate the role of basal forebrain (BF) in non-motor symptoms of Parkinson’s disease (PD), we investigated the association of sleep quality and cognition with BF volume and functional connectivity. The gray matter volume of the anterior intermediate part (Ch4ai) and the anterior lateral part (Ch4al) of the nucleus basalis Meynert were negatively associated with the PSQI global score. The posterior part of the nucleus basalis Meynert (Ch4p) volume was positively associated with visuospatial, memory, and executive functions. The PSQI global score correlated positively with functional connectivity from the Ch4al to the posterior cingulate, inferior parietal, anterior temporal, and medial prefrontal cortices, which correspond to the default mode network. Our results demonstrated that reduced volume of the anterior portion of the Ch4 and its aberrantly increased functional connectivity with the default mode network were closely related to poor overall sleep quality, while reduced volume of the posterior portion of the Ch4 was associated with decreased cognitive function in PD.
- Open Access
- 31 January 2025
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 18 (1) , 35-44
Efficacy and Safety of Taltirelin Hydrate in Patients With Ataxia Due to Spinocerebellar Degeneration
Objective We conducted this study to assess the efficacy and safety of taltirelin hydrate (TH) in patients with ataxia due to spinocerebellar degeneration (SCD).Methods Patients were randomly assigned to either the taltirelin group (5 mg orally, twice daily) or the control group. The primary endpoint was the change in the Korean version of the Scale for the Assessment and Rating of Ataxia (K-SARA) score at 24 weeks. The secondary endpoints included changes in the K-SARA score at 4 and 12 weeks as well as the Clinical Global Impression Scale, the five-level version of the EuroQol five-dimensional questionnaire, the Tinetti balance test, and gait analysis at 4, 12, and 24 weeks.Results A total of 149 patients (hereditary:nonhereditary=86:63) were enrolled. There were significant differences in the change in the K-SARA score at 24 weeks from baseline between the taltirelin group and the control group (-0.51±2.79 versus 0.36±2.62, respectively; p=0.0321). For the K-SARA items, the taltirelin group had significantly lower “Stance” and “Speech disturbance” subscores than the control group (-0.04±0.89 versus 0.23±0.79 and -0.07±0.74 versus 0.18±0.67; p=0.0270 and 0.0130, respectively). However, there were no significant differences in changes in other secondary efficacy outcome measures at 24 weeks from baseline between the two treatment arms (p>0.05).Conclusion Clinicians might consider the use of TH in the treatment of patients with ataxia due to SCD.
- 31 January 2025
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 18 (1) , 35-44
Open AccessEfficacy and Safety of Taltirelin Hydrate in Patients With Ataxia Due to Spinocerebellar Degeneration
Objective We conducted this study to assess the efficacy and safety of taltirelin hydrate (TH) in patients with ataxia due to spinocerebellar degeneration (SCD).Methods Patients were randomly assigned to either the taltirelin group (5 mg orally, twice daily) or the control group. The primary endpoint was the change in the Korean version of the Scale for the Assessment and Rating of Ataxia (K-SARA) score at 24 weeks. The secondary endpoints included changes in the K-SARA score at 4 and 12 weeks as well as the Clinical Global Impression Scale, the five-level version of the EuroQol five-dimensional questionnaire, the Tinetti balance test, and gait analysis at 4, 12, and 24 weeks.Results A total of 149 patients (hereditary:nonhereditary=86:63) were enrolled. There were significant differences in the change in the K-SARA score at 24 weeks from baseline between the taltirelin group and the control group (-0.51±2.79 versus 0.36±2.62, respectively; p=0.0321). For the K-SARA items, the taltirelin group had significantly lower “Stance” and “Speech disturbance” subscores than the control group (-0.04±0.89 versus 0.23±0.79 and -0.07±0.74 versus 0.18±0.67; p=0.0270 and 0.0130, respectively). However, there were no significant differences in changes in other secondary efficacy outcome measures at 24 weeks from baseline between the two treatment arms (p>0.05).Conclusion Clinicians might consider the use of TH in the treatment of patients with ataxia due to SCD.
- 24 December 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (12) , e210105
Association of Striatal Dopamine Depletion and Brain Metabolism Changes With Motor and Cognitive Deficits in Patients With Parkinson Disease
Parkinson disease (PD) shows degeneration of dopaminergic neurons in the substantia nigra and characteristic changes in brain metabolism. However, how they correlated and affect motor and cognitive dysfunction in PD has not yet been well elucidated. In this single-site cross-sectional study, we enrolled patients with PD who underwent N-(3-[18F]fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (18F-FP-CIT) PET, 18F-fluorodeoxyglucose (18F-FDG) PET, the Movement Disorder Society-sponsored Unified PD Rating Scale examination, and detailed neuropsychological testing. General linear models and mediation analyses were implemented to investigate the association between striatal dopamine transporter availability, brain metabolism, and parkinsonian motor subscores or domain-specific cognitive scores. Healthy controls (HCs) who underwent 18F-FP-CIT and 18F-FDG PET were also enrolled. Compared with HCs (n = 38, mean age 67.3 ± 5.9 years; 19 women), patients with PD (n = 143, mean age 69.0 ± 9.0 years; 69 women) characteristically showed relative brain hypermetabolism and hypometabolism that correlated with striatal dopamine transporter availability. As the loss of putaminal dopamine transporter availability increased, brain metabolism relatively increased from the paracentral lobule, pons, and limbic system to the cerebellum and anterior cingulate cortex, whereas brain metabolism relatively decreased from the lateral temporal and frontal cortices to the occipital and inferior parietal cortices. Reduced putaminal dopamine was associated with a higher rigidity subscore by the mediation of relative hypermetabolism in the paracentral lobule (standardized indirect effect, β = -0.070, p = 0.025) and directly associated with a higher bradykinesia subscore (β = -0.274, p = 0.011). Reduced caudate dopamine was associated with a higher axial subscore (β = -0.125, p = 0.004) and lower executive (β = 0.229, p = 0.004), visuospatial (β = 0.139, p = 0.006), and memory (β = 0.140, p = 0.004) domain scores by the mediation of relative brain hypometabolism. The tremor subscore and language and attention scores were not associated with striatal dopamine availability or brain metabolism. Our findings suggest that in PD, striatal dopamine depletion and altered brain metabolism are closely linked, that changes in brain metabolism occur in specific spatial patterns depending on the degree of dopamine depletion, and that both differentially affect motor and cognitive dysfunction depending on each symptom.
- 24 December 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 103 (12) , e210105
Association of Striatal Dopamine Depletion and Brain Metabolism Changes With Motor and Cognitive Deficits in Patients With Parkinson Disease
Parkinson disease (PD) shows degeneration of dopaminergic neurons in the substantia nigra and characteristic changes in brain metabolism. However, how they correlated and affect motor and cognitive dysfunction in PD has not yet been well elucidated. In this single-site cross-sectional study, we enrolled patients with PD who underwent N-(3-[18F]fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (18F-FP-CIT) PET, 18F-fluorodeoxyglucose (18F-FDG) PET, the Movement Disorder Society-sponsored Unified PD Rating Scale examination, and detailed neuropsychological testing. General linear models and mediation analyses were implemented to investigate the association between striatal dopamine transporter availability, brain metabolism, and parkinsonian motor subscores or domain-specific cognitive scores. Healthy controls (HCs) who underwent 18F-FP-CIT and 18F-FDG PET were also enrolled. Compared with HCs (n = 38, mean age 67.3 ± 5.9 years; 19 women), patients with PD (n = 143, mean age 69.0 ± 9.0 years; 69 women) characteristically showed relative brain hypermetabolism and hypometabolism that correlated with striatal dopamine transporter availability. As the loss of putaminal dopamine transporter availability increased, brain metabolism relatively increased from the paracentral lobule, pons, and limbic system to the cerebellum and anterior cingulate cortex, whereas brain metabolism relatively decreased from the lateral temporal and frontal cortices to the occipital and inferior parietal cortices. Reduced putaminal dopamine was associated with a higher rigidity subscore by the mediation of relative hypermetabolism in the paracentral lobule (standardized indirect effect, β = -0.070, p = 0.025) and directly associated with a higher bradykinesia subscore (β = -0.274, p = 0.011). Reduced caudate dopamine was associated with a higher axial subscore (β = -0.125, p = 0.004) and lower executive (β = 0.229, p = 0.004), visuospatial (β = 0.139, p = 0.006), and memory (β = 0.140, p = 0.004) domain scores by the mediation of relative brain hypometabolism. The tremor subscore and language and attention scores were not associated with striatal dopamine availability or brain metabolism. Our findings suggest that in PD, striatal dopamine depletion and altered brain metabolism are closely linked, that changes in brain metabolism occur in specific spatial patterns depending on the degree of dopamine depletion, and that both differentially affect motor and cognitive dysfunction depending on each symptom.